Sana Biotechnology/$SANA
1D1W1MYTD1Y5YMAX
Capital at risk
About Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
- Ticker
- $SANA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 142
- Headquarters
- Seattle, United States
- Website
- www.sana.com
SANA Metrics
BasicAdvanced
$958M
-
-$0.76
2.10
-
Price and volume
Market cap
$958M
Beta
2.1
52-week high
$6.55
52-week low
$2.61
Average daily volume
2.8M
Financial strength
Current ratio
1.379
Quick ratio
1.297
Long term debt to equity
0.427
Total debt to equity
0.524
Profitability
EBITDA (TTM)
-174.186
Management effectiveness
Return on assets (TTM)
-29.16%
Return on equity (TTM)
-152.87%
Valuation
Price to book
6.2
Price to tangible book (TTM)
-21.16
Price to free cash flow (TTM)
-6.572
Free cash flow yield (TTM)
-15.22%
Free cash flow per share (TTM)
-0.487
Growth
Earnings per share change (TTM)
-28.25%
3-year earnings per share growth (CAGR)
-26.13%
What the Analysts think about SANA
Analyst ratings (Buy, Hold, Sell) for Sana Biotechnology stock.
Analyst projections of the future price of Sana Biotechnology stock.
Bulls say / Bears say
Sana’s strategic collaboration with Mayo Clinic secured a $25 million equity investment and an option for an additional $25 million to accelerate SC451 development, validating its technology and extending its financial runway. (Reuters via Investing.com)
Fourteen-month data from an investigator-sponsored UP421 trial demonstrate survival and function of hypoimmune-modified islet cells without immunosuppression in a type 1 diabetes patient, supporting the clinical potential of Sana’s HIP platform. (Reuters via Investing.com)
With a Q2 2026 cash position of $160.5 million and an expected runway into mid-2027, Sana is positioned to fund key IND filings and Phase 1/2 clinical trials for SC451 and SG293 without immediate dilution. (Reuters)
Sana reported a Q2 2026 GAAP net loss of $63.6 million, underscoring the company’s high cash burn and potential funding risk beyond mid-2027 without additional financing. (Reuters)
In Q1 2026, the company generated zero revenue, highlighting its complete reliance on equity financings and partnerships to fund operations and advance its pipeline. (Reuters via Investing.com)
The SG293 in vivo CAR T program remains at the preclinical stage with only an ASGCT abstract acceptance and no IND filing timeline announced, illustrating significant execution and timeline risk before any clinical validation. (Reuters via Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
SANA Financial Performance
Revenues and expenses
SANA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SANA
AllUSDGBPEUR
Fund name | Fund size | $SANA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.